Top

Published in:

01-11-2013 | Review Article

Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients

Authors: Ourania Nicolatou-Galitis, Triantafyllia Sarri, Joanne Bowen, Mario Di Palma, Vassilios E. Kouloulias, Pasquale Niscola, Dorothea Riesenbeck, Monique Stokman, Wim Tissing, Eric Yeoh, Sharon Elad, Rajesh V. Lalla, For The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)

Published in: Supportive Care in Cancer | Issue 11/2013

Abstract

Purpose

The aim of this project was to review the available literature and define clinical practice guidelines for the use of anti-inflammatory agents for the prevention and treatment of oral mucositis in cancer patients.

Materials and methods

A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology. The body of evidence for use of each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: recommendation, suggestion, and no guideline possible.

Results

Forty-one papers were reviewed. There was sufficient evidence to recommend the use of benzydamine mouthwash for the prevention of oral mucositis in head and neck cancer patients receiving moderate-dose radiation therapy (up to 50 Gy), without concomitant chemotherapy. A new suggestion was developed against the use of misoprostol mouthwash for the prevention of oral mucositis in head and neck cancer patients receiving radiation therapy. Positive results were reported for some other anti-inflammatory agents. However, no guidelines were able to be developed for any other agents due to insufficient and/or conflicting evidence.

Conclusions

The use of anti-inflammatory agents continues to be a promising strategy for the prevention and treatment of oral mucositis. Additional well-designed studies are needed to examine the use of this class of agents for oral mucositis.

Sonis ST (1998) Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34:39–43PubMedCrossRef

Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl):1995–2025PubMedCrossRef

Xanthinaki A, Nicolatou-Galitis O, Athanassiadou P, Gonidi M, Kouloulias V, Sotiropoulou-Lontou A, Pissakas G, Kyprianou K, Kouvaris J, Patsouris E (2008) Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report. Support Care Cancer 16(9):1025–1033PubMedCrossRef

Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026–2046PubMedCrossRef

Lalla RV, Schubert MM, Bensadoun RJ, Keefe D (2006) Anti-inflammatory agents in the management of alimentary mucositis. Support Care Cancer 14(6):558–565PubMedCrossRef

Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109(5):820–831PubMedCrossRef

Bowen JM, Elad S, Hutchins RD, Lalla RV (2013) Methodology for the MASCC/ISOO Mucositis Clinical Practice Guidelines Update. Support Care Cancer 21:303–308PubMedCrossRef

Elad S, Bowen J, Zadik Y, Lalla RV (2013) Development of the MASCC/ISOO Clinical Practice Guidelines for Mucositis: considerations underlying the process. Support Care Cancer 21:309–312PubMedCrossRef

Hadorn DC, Baker D, Hodges JS, Hicks N (1996) Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 49(7):749–754PubMedCrossRef

10.

Somerfield MR, McCrae RR (2000) Stress and coping research. Methodological challenges, theoretical advances, and clinical applications. Am Psychol 55(6):620–6259PubMedCrossRef

11.

Nicolatou-Galitis O, Sarri T, Bowen J, Di Palma M, Kouloulias V, Niscola P et al (2013) Systematic review of amifostine for the management of oral mucositis in cancer patients. Support Care Cancer 21:357–364PubMedCrossRef

12.

Epstein JB, Stevenson-Moore P (1986) Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surg Oral Med Oral Pathol 62:145–148PubMedCrossRef

13.

Samaranayake LP, Robertson AG, MacFarlane TW, Hunter IP, MacFarlane G, Soutar DS, Ferguson MM (1988) The effect of chlorhexidine and benzydamine mouthwashes on mucositis induced by therapeutic irradiation. Clin Radiol 39:291–294PubMedCrossRef

14.

Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ (1989) Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse. Int J Radiat Oncol Biol Phys 16:1571–1575PubMedCrossRef

15.

Epstein JB, Silverman S Jr, Paggiarino DA, Crockett S, Schubert MM, Senzer NN, Lockhart PB, Gallagher MJ, Peterson DE, Leveque FG (2001) Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92:875–885PubMedCrossRef

16.

Cheng KF, Ka Tsui Yuen J (2006) A pilot study of chlorhexidine and benzydamine oral rinses for the prevention and treatment of irradiation mucositis in patients with head and neck cancer. Cancer Nurs 29:423–430CrossRef

17.

Kazemian A, Kamian S, Aghili M, Hashemi FA, Haddad P (2009) Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur J Cancer Care 18:174–178CrossRef

18.

Kim JH, Chu F, Lakshmi V, Houde R (1985) A clinical study of benzydamine for the treatment of radiotherapy-induced mucositis of the oropharynx. Int J Tissue React 7:215–218PubMed

19.

Kim JH, Chu FC, Lakshmi V, Houde R (1986) Benzydamine HCl, a new agent for the treatment of radiation mucositis of the oropharynx. Am J Clin Oncol 9:132–134PubMedCrossRef

20.

Prada A, Lozza L, Moglia D, Sala L, Chiesa F (1985) Effects of benzydamine on radio-polychemotherapeutic mucositis of the oral cavity. Int J Tissue React 7:237–239PubMed

21.

Prada A, Chiesa F (1987) Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy. Int J Tissue React 9:115–119PubMed

22.

Putwatana P, Sanmanowong P, Oonprasertpong L, Junda T, Pitiporn S, Narkwong L (2009) Relief of radiation-induced oral mucositis in head and neck cancer. Cancer Nurs 32:82–87PubMedCrossRef

23.

Cheng KK, Chang AM (2003) Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy. Cancer Nurs 26:476–484PubMedCrossRef

24.

Cheng KK, Chang AM, Yuen MP (2004) Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care. Eur J Cancer 40:1208–1216PubMedCrossRef

25.

Cheng KK (2004) Children's acceptance and tolerance of chlorhexidine and benzydamine oral rinses in the treatment of chemotherapy-induced oropharyngeal mucositis. Eur J Oncol Nurs 8:341–349PubMedCrossRef

26.

Sonis ST, Clairmont F, Lockhart PB, Connolly SF (1985) Benzydamine HCL in the management of chemotherapy-induced mucositis I. Pilot study. J Oral Med 40:67–71PubMed

27.

Schubert MM, Newton RE (1987) The use of benzydamine HCl for the management of cancer therapy-induced mucositis: preliminary report of a multicentre study. Int J Tissue React 9:99–103PubMed

28.

Lever SA, Dupuis LL, Chan HS (1987) Comparative evaluation of benzydamine oral rinse in children with antineoplastic-induced stomatitis. Drug Intell Clin Pharm 21:359–361PubMed

29.

Rothwell BR, Spektor WS (1990) Palliation of radiation-related mucositis. Spec Care Dentist 10:21–25PubMedCrossRef

30.

Carnel SB, Blakeslee DB, Oswald SG, Barnes M (1990) Treatment of radiation- and chemotherapy-induced stomatitis. Otolaryngol Head Neck Surg 102:326–330PubMed

31.

Barker G, Loftus L, Cuddy P, Barker B (1991) The effects of sucralfate suspension and diphenhydramine syrup plus kaolin–pectin on radiotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol 71:288–293PubMedCrossRef

32.

Turhal NS, Erdal S, Karacay S (2000) Efficacy of treatment to relieve mucositis-induced discomfort. Support Care Cancer 8:55–58PubMed

33.

Dodd MJ, Dibble SL, Miaskowski C, MacPhail L, Greenspan D, Paul SM, Shiba G, Larson P (2000) Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90:39–47PubMedCrossRef

34.

Porteder H, Rausch E, Kment G, Watzek G, Matejka M, Sinzinger H (1988) Local prostaglandin E2 in patients with oral malignancies undergoing chemo- and radiotherapy. J Craniomaxillofac Surg 16:371–374PubMedCrossRef

35.

Labar B, Mrsic M, Pavletic Z, Bogdanic V, Nemet D, Aurer I, Radman I, Filipovic-Grcic N, Sertic D, Kalenic S et al (1993) Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 11:379–382PubMed

36.

Kuhrer I, Kuzmits R, Linkesch W, Ludwig H (1986) Topical PGE2 enhances healing of chemotherapy-associated mucosal lesions. Lancet 1(8481):623PubMedCrossRef

37.

Pretnar J, Glazar D, Mlakar U, Modic M (1989) Prostaglandin E2 in the treatment of oral mucositis due to radiochemotherapy in patients with haematological malignancies. Bone Marrow Transplant 4(Suppl 3):106PubMed

38.

Duenas-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M, Gallardo-Rincon D, Lara-Medina F, Aguilar-Ponce L, Miranda-Lopez E, Zinser-Sierra J, Reynoso-Gomez E (1996) Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. Bone Marrow Transplant 17:809–812PubMed

39.

Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE, Tova Y (1997) Protection from radiation-induced oral mucositis by a mouth rinse containing the prostaglandin E1 analog, misoprostol: a placebo controlled double blind clinical trial. Adv Exp Med Biol 400B:811–818PubMed

40.

Veness MJ, Foroudi F, Gebski V, Timms I, Sathiyaseelan Y, Cakir B, Tiver KW (2006) Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial. Australas Radiol 50:468–474PubMedCrossRef

41.

Mose S, Adamietz IA, Saran F, Thilmann C, Heyd R, Knecht R, Bottcher HD (1997) Can prophylactic application of immunoglobulin decrease radiotherapy-induced oral mucositis? Am J Clin Oncol 20:407–411PubMedCrossRef

42.

Plevova P, Blazek B (1997) Intravenous immunoglobulin as prophylaxis of chemotherapy-induced oral mucositis. J Natl Cancer Inst 89:326–327PubMedCrossRef

43.

Abdelaal AS, Barker DS, Fergusson MM (1989) Treatment for irradiation-induced mucositis. Lancet 1(8629):97PubMedCrossRef

44.

Leborgne JH, Leborgne F, Zubizarreta E, Ortega B, Mezzera J (1998) Corticosteroids and radiation mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial. Radiother Oncol 47:145–148PubMedCrossRef

45.

Pillsbury HC 3rd, Webster WP, Rosenman J (1986) Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Arch Otolaryngol Head Neck Surg 112:552–553PubMedCrossRef

46.

Osaki T, Ueta E, Yoneda K, Hirota J, Yamamoto T (1994) Prophylaxis of oral mucositis associated with chemoradiotherapy for oral carcinoma by Azelastine hydrochloride (Azelastine) with other antioxidants. Head Neck 16:331–339PubMedCrossRef

47.

Rymes N, Glick L, Holmes JA (1996) Topical mesalazine in the treatment of chemotherapy and radiotherapy-induced oral mucositis. Bone Marrow Transplant 18:484PubMed

48.

Kaushal V, Verma K, Manocha S, Hooda HS, Das BP (2001) Clinical evaluation of human placental extract (placentrex) in radiation-induced oral mucositis. Int J Tissue React 23:105–110PubMed

49.

Valencia J, Velilla C, Urpegui A, Alvarez I, Llorens MA, Coronel P, Polo S, Bascon N, Esco R (2002) The efficacy of orgotein in the treatment of acute toxicity due to radiotherapy on head and neck tumors. Tumori 88:385–389PubMed

50.

Stokman MA, Spijkervet FK, Burlage FR, Roodenburg JL (2005) Clinical effects of flurbiprofen tooth patch on radiation-induced oral mucositis. A pilot study. Support Care Cancer 13:42–48PubMedCrossRef

51.

Elad S, Ackerstein A, Bitan M, Shapira MY, Resnick I, Gesundheit B, Cohen Y, Diss O, Barak D, Dray L, Or R (2006) A prospective, double-blind phase II study evaluating the safety and efficacy of a topical histamine gel for the prophylaxis of oral mucositis in patients post hematopoietic stem cell transplantation. Bone Marrow Transplant 37:757–762PubMedCrossRef

52.

Garavito AA, Cardona AF, Reveiz L, Ospina E, Yepes A, Ospina V (2008) Colchicine mouth washings to improve oral mucositis in patients with hematological malignancies: a clinical trial. Palliat Support Care 6:371–376PubMedCrossRef

53.

Sonis ST, Peterson RL, Edwards LJ, Lucey CA, Wang L, Mason L et al (2000) Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 36:373–381PubMedCrossRef

54.

Logan RM, Gibson RJ, Sonis ST, Keefe DMK (2007) Nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 43:395–401PubMedCrossRef

55.

Sironi M, Pozzi P, Polentarutti N, Benigni F, Coletta I, Guglielmotti A, Milanese C, Ghezzi P, Vecchi A, Pinza M, Mantovani A (1996) Inhibition of inflammatory cytokine production and protection against endotoxin toxicity by benzydamine. Cytokine 8(9):710–716PubMedCrossRef

56.

Sironi M, Milanese C, Vecchi A, Polenzani L, Guglielmotti A, Coletta I, Landolfi C, Soldo L, Mantovani A, Pinza M (1997) Benzydamine inhibits the release of tumor necrosis factor-alpha and monocyte chemotactic protein-1 by Candida albicans-stimulated human peripheral blood cells. Int J Clin Lab Res 27:118–122PubMedCrossRef

57.

Lalla RV, Gordon GB, Schubert M, Silverman S Jr, Hutten M, Sonis ST et al (2012) A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy. Support Care Cancer 20:1797–1804PubMedCrossRef

Title: Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients
Authors: Ourania Nicolatou-Galitis
Triantafyllia Sarri
Joanne Bowen
Mario Di Palma
Vassilios E. Kouloulias
Pasquale Niscola
Dorothea Riesenbeck
Monique Stokman
Wim Tissing
Eric Yeoh
Sharon Elad
Rajesh V. Lalla
For The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)
Publication date: 01-11-2013
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 11/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-013-1847-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2013

Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation

Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients

Dr. Yojiro Ota

Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients

Excess risk of Clostridium difficile infection in ovarian cancer is related to exposure to broad-spectrum antibiotics

Comparison of modified Borg scale and visual analog scale dyspnea scores in predicting re-intervention after drainage of malignant pleural effusion

Keynote webinar | Spotlight on antibody–drug conjugates in cancer